Targeted Therapy |

Blog Archives

Hope for patients with cutaneous squamous cell carcinoma (CSCC): Cemiplimab-Rwlc (Libtayo)

Posted on October 30, 2018 by by

Joseph Gut - thasso Posted in New Drug Approval, Personalized Medicine, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

October 31, 2018 – The American Food and Drug Administration (FDA) recently approved Cemiplimab-Rwlc (Libtayo) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

…

Patisiran (Onpattro): First targeted RNA-based therapy approved to treat hATTR

Posted on August 13, 2018 by by

Joseph Gut - thasso Posted in Genetic Background, New Drug Approval, Rare Diseases, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

August 14, 2018 – The American Food and Drug Administration (FDA) just approved Patisiran (Onpattro) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.

…

Cancer is not like cancer: Ethnic background matters

Posted on November 24, 2017 by by

Joseph Gut - thasso Posted in Ethnicity, Genetic Background, New Research, Personalized Medicine, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

November 24, 2017 – New research indicates that one-size treatment for one form of blood cancer likely does not fit all, particularly when it comes to ethnic differences of patients. Thus, African-American men are three times more likely to be diagnosed with multiple myeloma,

…

Besponsa: Is this really a viable new treatment for ALL?

Posted on August 18, 2017 by by

Joseph Gut - thasso Posted in New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

August 18, 2017 – B-cell precursor acute lymphoblastic leukemia (ALL) is a aggressive and rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. In the United States, the National Cancer Institute estimates that approximately 5,970 people will be diagnosed with B-cell ALL this year and approximately 1,440 will die from the disease.

…

Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy (DMD) approved

Posted on September 20, 2016 by by

Joseph Gut - thasso Posted in Genetic Background, In The Press, New Drug Approval, Personalized Medicine, Pharmacogenetics, Rare Diseases, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine 1 Comment ↓

September 19, 2016 – This post presents below a virtually unedited announcement by the American Food & Drug Administration (FDA) concerning Duchenne Muscular Dystrophy (DMD) therapy option which gives much hope for at least some of the affected patients.

…

The HCV saga goes on: Epclusa has been approved for treatment of chronic Hepatitis C virus (HCV) infection

Posted on June 29, 2016 by by

Joseph Gut - thasso Posted in New Drug Approval, Thasso Post, Theragenomic Medicine No Comments ↓

…

Hope for patients with urothelial carcinoma: Atezolizumab (Tecentriq) approved

Posted on May 20, 2016 by by

Joseph Gut - thasso Posted in New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

May 18, 2016 – Over the last two years, biologics targeting the PD-1/PD-L1 pathway (proteins found on the body’s immune cells and some cancer cells), notably Nivolumab (Opdivo) and Pembrolizumab (Keytruda), have come to the clinic for the treatment of a selection of oncologic indications.

…

Venetoclax (Venclexta) for the treatment of patients with chronic lymphocytic leukemia (CLL)

Posted on April 12, 2016 by by

Joseph Gut - thasso Posted in New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

April 12, 2016 – The American Food and Drug Administration (FDA) just approved Venetoclax (Venclexta) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with a least one prior therapy.

…

Theragenomic Medicine: Gefinitib (Iressa) targeted therapy for first-line treatment of patients with a type of metastatic lung cancer approved

Posted on July 14, 2015 by by

Joseph Gut - thasso Posted in Allelische Variante, New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

July 13, 2015 – This post persents a press announcement by the U.S. Food and Drug Administration (FDA). The text has slightly been edited by the autor of this blog. Thus, FDA today approved Gefinitib (Iressa) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene mutations,

…

Theragenomic Medicine: Targeted Therapies and Associated Toxicity

Posted on March 22, 2015 by by

Joseph Gut - thasso Posted in Adverse Drug Reaction [ADR], Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

March 22, 2015 – This post addresses a topic which often gets lost in the current hype on targeted and precision (theragenomic) medicine. The issue is that targeted therapies are not only very precise and highly effective (in most patients) but they often also come with considerable clinical toxicity.

…